Multisystem Inflammatory Syndrome Associated with COVID-19 Case Report Form, May 28, 2021
Casirivimab and Imdevimab—Administration together for mild to moderate coronavirus disease in adults and pediatric patients 12 years of age and older and weighing at least 40 kg with positive viral testing results, and who are at high risk for progressing to severe COVID-19.
Baricitinib (Olumiant) in combination with remdesivir (Veklury)—Emergency use for suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
Bamlanivimab—Treatment of mild to moderate COVID-19 in adult and pediatric patients with positive SARS-CoV-2 viral testing results and age 12 years and older and weighing at least 40 kilograms
COVID-19 convalescent plasma—Treatment of hospitalized patients with COVID-19
Regiocit replacement solution—Replacement solution only in adult patients treated with continuous renal replacement therapy (CRRT)
Fresenius Kabi Propoven 2%—Maintaining sedation via continuous infusion in patients older than 16 years with suspected or confirmed COVID-10 who require mechanical ventilation in an ICU
Remdesivir for certain hospitalized COVID-19 Patients—Emergency use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg